The rise of the large-volume purchaser of health care scared the industry's strategists into hyperactivity, prompting moves-most prominently by Merck, SmithKline and Lilly-into the service business. These services were designed to take pricing pressure off the companies' core businesses by putting the cost of products into a larger context and helping customers save money in other areas; in the process perhaps also creating another revenue stream for the manufacturer.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.